Christopher Waynick, MD
Hematology & Oncology · Murfreesboro, TNNPI 1780819375
Payments from drug & device makers
Across 445 payments — averaging $31.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Bayer$2K
- AstraZeneca$910
- Novartis$610
- Merck$598
- Bristol Myers Squibb$448
- plus $6K from 54 others
What the payments were for
- Consulting fees$4,62533%
- Travel & lodging$350%
- Food & beverage$8,97465%
- Education$2392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,874 in reported general payments places this provider in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 51 | $834,494 |
| XtandiEnzalutamide | 41 | $566,743 |
| PomalystPomalidomide | 23 | $448,479 |
| IbrancePalbociclib | 29 | $439,831 |
| NubeqaDarolutamide | 19 | $250,575 |
| KisqaliRibociclib Succinate | 14 | $217,105 |
| CalquenceAcalabrutinib Maleate | 20 | $206,720 |
| JakafiRuxolitinib Phosphate | 11 | $179,529 |
| ErleadaApalutamide | 11 | $164,457 |
| LonsurfTrifluridine/Tipiracil Hcl | 14 | $147,308 |
| EliquisApixaban | 49 | $42,519 |
| OrgovyxRelugolix | 12 | $33,096 |
| XareltoRivaroxaban | 33 | $28,626 |
| Anastrozole | 79 | $1,812 |
| Dexamethasone | 90 | $1,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $448 | $834,49451 claims |
| Astellas Pharma US IncXtandi | $234 | $566,74341 claims |
| PfizerIbrance, Eliquis | $169 | $482,35078 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $426 | $448,47923 claims |
| BayerNubeqa | $1,919 | $250,57519 claims |
| NovartisKisqali | $610 | $217,10514 claims |
| AstraZenecaCalquence | $910 | $206,72020 claims |
| Johnson & JohnsonErleada, Xarelto | $3,538 | $193,08344 claims |
| Incyte CorporationJakafi | $253 | $179,52911 claims |
| Taiho Oncology, Inc.Lonsurf | $73 | $147,30814 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $34 | $34640 claims |
| Lilly USA, LLCOlanzapine | $182 | $25912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Murfreesboro
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
- Krish PatelNashville$14.2M
- Kathryn BeckermannFranklin$13.6M
- Denise YardleyNashville$13.2M
- Todd BauerNashville$10.9M
- Bertrand AnzChattanooga$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.